Literature DB >> 9461474

alpha-Oligodeoxyribonucleotide N3'-->P5' phosphoramidates: synthesis and duplex formation.

K Pongracz1, S M Gryaznov.   

Abstract

The synthesis and hybridization properties of novel nucleic acid analogs, alpha-anomeric oligodeoxyribonucleotide N3'-->P5' phosphoramidates, are described. The alpha-3'-aminonucleoside building blocks used for oligonucleotide synthesis were synthesized from 3'-azido-3'-deoxythymidine or 3'-azido-2',3'-dideoxyuridine via acid catalyzed anomerization or transglycosylation reactions. The base-protected alpha-5'-O-DMT-3'-aminonucleosides were assembled into dimers and oligonucleotides on a solid support using the oxidative phosphorylation method.1H NMR analysis of the alpha-N3'-->P5' phosphoramidate dimer structures indicates significant differences in the sugar puckering of these compounds relative to the beta-N3'-->P5' phosphoramidates and to the alpha-phosphodiester counterparts. Additionally, the ability of the alpha-oligonucleotide N3'-->P5' phosphoramidates to form duplexes was studied using thermal denaturation experiments. Thus the N3'-->P5' phosphoramidate decamer containing only alpha-thymidine residues did not bind to poly(A) and exhibited lower duplex thermal stability with poly(dA) than that for the corresponding beta-anomeric phosphoramidate counterpart. A mixed base decamer alpha-CTTCTTCCTT formed duplexes with the RNA and DNA complementary strands only in a parallel orientation. Melting temperatures of these complexes were significantly lower, by 34-47 or 15-25 degrees C, than for the duplexes formed by the isosequential beta-phosphoramidates in antiparallel and parallel orientations respectively. In contrast, the alpha-decaadenylic N3'-->P5' phosphoramidate formed duplexes with both RNA and DNA complementary strands with a stability similar to that of the corresponding beta-anomeric phosphoramidate. Moreover, the self-complementary oligonucleotide alpha-ATATATATAT did not form an alpha:alpha homoduplex. These results demonstrate the effects of 3'-aminonucleoside anomeric configuration on sugar puckering and consequently on stability of the duplexes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9461474      PMCID: PMC147364          DOI: 10.1093/nar/26.4.1099

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  32 in total

1.  Oligonucleotide N3'-->P5' phosphoramidates.

Authors:  S M Gryaznov; D H Lloyd; J K Chen; R G Schultz; L A DeDionisio; L Ratmeyer; W D Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

Review 2.  The interaction of intercalators and groove-binding agents with DNA triple-helical structures: the influence of ligand structure, DNA backbone modifications and sequence.

Authors:  W D Wilson; S Mizan; F A Tanious; S Yao; G Zon
Journal:  J Mol Recognit       Date:  1994-06       Impact factor: 2.137

Review 3.  Current concepts in antisense drug design.

Authors:  J F Milligan; M D Matteucci; J C Martin
Journal:  J Med Chem       Date:  1993-07-09       Impact factor: 7.446

4.  Triple helix formation by alpha-oligodeoxynucleotides: a vibrational spectroscopy and molecular modeling study.

Authors:  J Liquier; R Letellier; C Dagneaux; M Ouali; F Morvan; B Raynier; J L Imbach; E Taillandier
Journal:  Biochemistry       Date:  1993-10-12       Impact factor: 3.162

5.  A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts.

Authors:  S T Crooke; L R Grillone; A Tendolkar; A Garrett; M J Fratkin; J Leeds; W H Barr
Journal:  Clin Pharmacol Ther       Date:  1994-12       Impact factor: 6.875

6.  Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial.

Authors:  E Bayever; P L Iversen; M R Bishop; J G Sharp; H K Tewary; M A Arneson; S J Pirruccello; R W Ruddon; A Kessinger; G Zon
Journal:  Antisense Res Dev       Date:  1993

Review 7.  Backbone modifications in oligonucleotides and peptide nucleic acid systems.

Authors:  A De Mesmaeker; K H Altmann; A Waldner; S Wendeborn
Journal:  Curr Opin Struct Biol       Date:  1995-06       Impact factor: 6.809

8.  Synthesis of oligodeoxyribonucleotide N3'-->P5' phosphoramidates.

Authors:  J K Chen; R G Schultz; D H Lloyd; S M Gryaznov
Journal:  Nucleic Acids Res       Date:  1995-07-25       Impact factor: 16.971

9.  Chimeric alpha-beta oligonucleotides as antisense inhibitors of reverse transcription.

Authors:  C Boiziau; F Debart; B Rayner; J L Imbach; J J Toulme
Journal:  FEBS Lett       Date:  1995-03-13       Impact factor: 4.124

10.  Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.

Authors:  R Zhang; J Yan; H K Shahinian; H Shahinian; G Amin; Z Lu; T Liu; M S Saag; Z Jiang; J Temsamani; R R Martin
Journal:  Clin Pharmacol Ther       Date:  1995-07       Impact factor: 6.875

View more
  1 in total

1.  New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163.

Authors:  Rintaro Hashizume; Tomoko Ozawa; Sergei M Gryaznov; Andrew W Bollen; Kathleen R Lamborn; William H Frey; Dennis F Deen
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.